GB1442796A - Method for purification of physiologically active substance using enzyme-enzyme inhibitor system - Google Patents

Method for purification of physiologically active substance using enzyme-enzyme inhibitor system

Info

Publication number
GB1442796A
GB1442796A GB5868773A GB5868773A GB1442796A GB 1442796 A GB1442796 A GB 1442796A GB 5868773 A GB5868773 A GB 5868773A GB 5868773 A GB5868773 A GB 5868773A GB 1442796 A GB1442796 A GB 1442796A
Authority
GB
United Kingdom
Prior art keywords
enzyme
inhibitor
insolubilized
proteolytic
enzymes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB5868773A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ono Pharmaceutical Co Ltd
Original Assignee
Ono Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co Ltd filed Critical Ono Pharmaceutical Co Ltd
Publication of GB1442796A publication Critical patent/GB1442796A/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6445—Kallikreins (3.4.21.34; 3.4.21.35)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6427—Chymotrypsins (3.4.21.1; 3.4.21.2); Trypsin (3.4.21.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

1442796 Isolating and purifying proteolytic enzymes and inhibitors ONO PHARMACEUTICAL CO Ltd 18 Dec 1973 [19 Dec 1972] 58687/73 Heading C3H A method of isolating and purifying a physiologically active substance, defined as meaning either proteolytic enzymes which take part in the production-consumption of kinin or an inhibitor which is proteinaceous in nature and inhibits the activity of the above proteolytic enzyme, contained in mammalian tissue or body fluid comprises the steps of passing an extract of said tissue or a diluted solution of said body fluid through a combination of columns packed with an insolubilized naturally occurring proteolytic enzyme and an insolubilized naturally occurring proteolytic enzyme inhibitor corresponding to the enzyme, respectively, in a continuous manner to adsorb the corresponding enzyme inhibitors present in the extract or diluted solution on to the insolubilized enzyme and the corresponding enzymes present in the extract or diluted solution on to the insolubilized enzyme inhibitor, respectively, and eluting separately the adsorbed enzyme inhibitors and enzymes from the columns to obtain fractions containing the physiologically active substances. The proteolytic enzyme may be kallikrein, plasmin, thrombin, trypsin, or chymotrypsin and the proteolytic enzyme inhibitor may be the corresponding inhibitor to these enzymes. Preferably the insolubilized enzyme/inhibitor system comprises the proteolytic enzyme inhibitor bound to an insoluble agarose, dextran or polyacrylamide carrier and the proteolytic enzyme chemically bound to an insoluble agarose, dextran or polyacrylamide carrier.
GB5868773A 1972-12-19 1973-12-18 Method for purification of physiologically active substance using enzyme-enzyme inhibitor system Expired GB1442796A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP12739672A JPS5325030B2 (en) 1972-12-19 1972-12-19

Publications (1)

Publication Number Publication Date
GB1442796A true GB1442796A (en) 1976-07-14

Family

ID=14958946

Family Applications (1)

Application Number Title Priority Date Filing Date
GB5868773A Expired GB1442796A (en) 1972-12-19 1973-12-18 Method for purification of physiologically active substance using enzyme-enzyme inhibitor system

Country Status (4)

Country Link
JP (1) JPS5325030B2 (en)
DE (1) DE2363201B2 (en)
FR (1) FR2210620B1 (en)
GB (1) GB1442796A (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT943553B (en) * 1971-06-25 1973-04-10 A Ciferri PROCEDURE FOR MODIFYING SOME PHYSICAL-MECHANICAL CHARACTERISTICS OF POLYMER MATERIALS CONTAINING POLAR GROUPS
US4030977A (en) * 1972-12-19 1977-06-21 Ono Pharmaceutical Co., Ltd. Method for purification of physiologically active substance using enzyme-enzyme inhibitor system
DE2612479A1 (en) * 1975-04-18 1976-10-21 Behringwerke Ag PROCEDURE FOR PREGNANCY-SPECIFIC PREGNANCY-SPECIFIC BETA LOW 1-GLYCOPROTEIN ENrichment
JPS5462312A (en) * 1977-10-28 1979-05-19 Tokyo Zouki Kagaku Kk Purifying of kariclein
DE3034043A1 (en) * 1980-09-10 1982-04-22 Boehringer Mannheim Gmbh, 6800 Mannheim METHOD FOR SELECTIVE SEPARATION OF ENDOPROTEASES
DE3103257A1 (en) * 1981-01-31 1982-08-26 Bayer Ag, 5090 Leverkusen METHOD FOR PRODUCING THE HIGH PURITY ENZYME KALLIKREIN FROM PIG PANCREAS EXTRACTS
AU538170B2 (en) * 1982-09-15 1984-08-02 Owens-Illinois Glass Container Inc. Modified protein to mould an enzyme type molecule
AU539729B2 (en) * 1982-09-16 1984-10-11 Owens-Illinois Glass Container Inc. Protein moulding to form semi-synthetic enzymes
AU538942B2 (en) * 1982-09-16 1984-09-06 Owens-Illinois Glass Container Inc. Protein moulding to make enzyme-type action and immobilization
JPS59109172A (en) * 1982-12-13 1984-06-23 Ss Pharmaceut Co Ltd Purification of kallikrein
JPS61247749A (en) * 1985-04-26 1986-11-05 Asahi Chem Ind Co Ltd Acrylonitrile polymer containing metal or metallic compound
BE1006312A3 (en) * 1991-11-29 1994-07-19 Univ Catholique Louvain Selection process for recombinant microorganisms with their area at least one molecule enzymatic activity.

Also Published As

Publication number Publication date
FR2210620B1 (en) 1978-02-10
DE2363201B2 (en) 1980-07-31
FR2210620A1 (en) 1974-07-12
DE2363201A1 (en) 1974-07-04
JPS5325030B2 (en) 1978-07-24
JPS504227A (en) 1975-01-17

Similar Documents

Publication Publication Date Title
Mosher et al. Synthesis and secretion of alpha2-macroglobulin by cultured human fibroblasts.
GB1442796A (en) Method for purification of physiologically active substance using enzyme-enzyme inhibitor system
CA1267496C (en) Purification and activation of proteins from insoluble inclusion bodies
SE8200715L (en) PYROGEN CONTENT REDUCTION
ZA866250B (en) Purification and activation of proteins from insoluble inclusion bodies
EP0313346A2 (en) Cysteine proteinases, production and use
DE3650135D1 (en) Protein extraction.
AU591879B2 (en) A method for purifying a physiologically active substance produced by recombinant DNA technique
ES8607243A1 (en) Chromogenic amino acids and peptide esters, process for their preparation, use of these compounds in analytical processes, as well as agents for marking esterolytic and/or proteolytic enzymes.
DE59009945D1 (en) AGENT FOR INHIBITING HIV PROTEASES.
Yoshida et al. Modulation of the receptor for urokinase-type plasminogen activator in macrophage-like U937 cells by inflammatory mediators
GB1401737A (en) Anti-coagulant isolation
ATE73500T1 (en) ANALYTICAL METHODS AND MEANS FOR DETECTING ESTEROLYTIC AND/OR PROTEOLYTIC ENZYMES.
ES309630A1 (en) Procedure for the preparation of an anticoagulant material. (Machine-translation by Google Translate, not legally binding)
Vahtera et al. Absence of binding of pancreatic and urinary kallikreins to α 2-macroglobulin
ES447851A1 (en) Process for the extraction of components having anticoagulant activity {37 in vivo{38 {0 from snake venoms and products obtained
IE34463B1 (en) Enzymes
DK307384A (en) NEW PLASMINOGEN ACTIVATOR AND METHOD FOR PREPARING THEM AND THROMBOLYTIC AGENTS CONTAINING SAME
NO861408L (en) PROCEDURE FOR CLEANING PLASMINOGEN ACTIVATORS (PA).
GB1423913A (en) Purification of orgotein
JPS6463378A (en) Separation of single stranded tpa and double standard tpa
Reddy et al. Differential autolysis of human and canine plasmins
Horton et al. A comparison of the plasma kinin forming enzymes in urine; kallikrein and urokinase
Bunning et al. The Effects of Mononuclear Cell Factor/Interleukin-1 on the Plasminogen Activators Produced by Human Chondrocytes
Jang et al. Changes in the RNA and Protein Synthesis at the Pre-and Post fertilization Stages of a Sea Urchin, Hemicentrotus pulcherrimus

Legal Events

Date Code Title Description
PS Patent sealed
PCNP Patent ceased through non-payment of renewal fee